Depression is often discussed as a major mental health concern among women diagnosed with ovarian cancer. Many studies have suggested that patients with ovarian cancer experience depression at significantly higher rates than the general population. However, new research published in the journal Cancer raises an important question: are standard depression screening tools accurately measuring depression in ovarian cancer patients, or are they confusing cancer-related physical symptoms with psychological distress?
The study, titled “Rethinking Depression Diagnosis in Ovarian Cancer: The Role of Somatic Symptoms,” explores how physical symptoms linked to ovarian cancer may inflate depression scores during diagnosis and treatment. Researchers found that symptoms such as fatigue, appetite loss, sleep disruption, and difficulty concentrating may not always indicate clinical depression. Instead, these symptoms can stem directly from the disease process itself.
This research highlights the urgent need for more accurate mental health screening methods in oncology care, especially for women coping with ovarian cancer.
Ovarian cancer remains one of the deadliest gynecologic cancers worldwide. Because many patients are diagnosed at an advanced stage, the emotional and physical burden can be overwhelming. Previous studies have reported that more than 25% of ovarian cancer patients may meet the criteria for depressive disorders before treatment begins.
At first glance, these statistics suggest a severe mental health crisis among ovarian cancer patients. However, the new study argues that traditional depression questionnaires may overestimate depression severity because many physical symptoms of cancer overlap with symptoms used to diagnose depression.
For example, depression assessments often include questions about:
These are also common symptoms experienced by ovarian cancer patients due to tumor burden, inflammation, surgery, chemotherapy, and general illness-related stress.
As a result, a patient may score high on a depression test even when they are not clinically depressed.
The study was conducted by researchers including Rachel Telles, Premal H. Thaker, and Susan K. Lutgendorf.
Researchers analyzed data from 428 women diagnosed with ovarian cancer. Participants completed psychological assessments shortly before surgery or chemotherapy and again one year later. The team also compared their results with a healthy control group from the well-known Midlife in the United States Study.
To measure depressive symptoms, the researchers used the widely recognized Center for Epidemiologic Studies Depression Scale, commonly known as the CES-D.
The goal was to determine whether somatic symptoms, meaning physical symptoms associated with illness, were influencing depression scores differently in ovarian cancer patients compared to healthy adults.
The results revealed several important insights.
Women with ovarian cancer were more likely to report physical symptoms associated with depression even at lower levels of actual psychological distress.
In other words, patients endorsed symptoms like fatigue and appetite loss before they showed stronger emotional symptoms such as sadness or hopelessness.
This suggests that cancer-related physical symptoms may artificially raise depression scores during diagnosis and early treatment.
The study found that nonsomatic symptoms, including sadness, despair, and loss of pleasure, were more strongly connected to genuine depression than physical symptoms.
This finding is important because it indicates clinicians should focus more carefully on emotional and cognitive symptoms when evaluating depression in ovarian cancer patients.
Interestingly, the gap between ovarian cancer patients and healthy controls became much smaller one year after diagnosis.
Once treatment was completed and disease-related physical symptoms decreased, depression assessments became more comparable between the two groups.
This supports the idea that the early stages of cancer treatment may distort depression screening results.
Accurate mental health assessment is critical in oncology. Depression can negatively affect:
At the same time, overdiagnosing depression can also create problems. Patients may receive unnecessary psychiatric labels, inappropriate medications, or increased emotional burden from being told they are clinically depressed.
The findings suggest healthcare providers should use a more nuanced approach when screening ovarian cancer patients for depression.
Rather than relying heavily on physical symptom scores alone, clinicians may need to prioritize emotional symptoms and clinical interviews.
One of the biggest challenges in psycho-oncology is separating “sickness behavior” from major depressive disorder.
Cancer-related inflammation can trigger symptoms that closely resemble depression. These may include:
These symptoms are biologically linked to cancer and treatment, not necessarily to psychiatric illness.
The study argues that traditional screening tools may not fully account for this distinction.
This is especially important in ovarian cancer because the disease often causes substantial physical discomfort before treatment even begins.
The researchers emphasize the need for improved depression measurement tools specifically designed for cancer populations.
Future assessments may benefit from:
The study also highlights the need for more research involving diverse patient populations, as most participants in the study were White and non-Hispanic.
Understanding how depression presents across different cultural and demographic groups remains an important area for future investigation.
The findings support a broader movement toward personalized medicine in cancer care.
Mental health screening should not follow a one-size-fits-all model. Instead, clinicians should consider:
Patients newly diagnosed with ovarian cancer may benefit most from supportive counseling, symptom management, and psychoeducation rather than immediate assumptions of major depressive disorder.
This approach could help reduce unnecessary stigma while still ensuring patients with true clinical depression receive proper care.
The new study on ovarian cancer and depression diagnosis challenges long-held assumptions about how depressive symptoms are measured in cancer patients. Researchers found that physical symptoms commonly associated with ovarian cancer may inflate depression scores during diagnosis and treatment.
Although depression remains a serious concern among ovarian cancer patients, the study suggests that clinicians should interpret screening results carefully and place greater emphasis on emotional symptoms rather than somatic complaints alone.
As cancer care continues to evolve, more accurate and personalized mental health assessments may improve both psychological support and overall patient outcomes.
Telles R, Thaker PH, Goodheart MJ, Penedo FJ, Sood AK, Lutgendorf SK. Rethinking depression diagnosis in ovarian cancer: The role of somatic symptoms. Published May 11, 2026. DOI: 10.1002/cncr.70344.
This article is intended for educational and informational purposes only. It does not provide medical advice, diagnosis, or treatment recommendations. Readers should consult qualified healthcare professionals regarding any medical or mental health concerns related to ovarian cancer or depression.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.